-
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-12 Tony Kirby
No Abstract
-
Historic TB outbreak a wake-up call for US policy makers Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-12 Bryant Furlow
No Abstract
-
Epidemiology and management of paediatric pulmonary embolism: a much-needed focus of research Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-12 Kaiyuan Zhen, Peiran Yang, Zhenguo Zhai
No Abstract
-
Current Smoker: A Clinical COPD Phenotype Affecting Disease Progression and Response to Therapy. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-12 Bartolome R Celli,Stephanie A Christenson,Klaus F Rabe,MeiLan K Han,Maarten van den Berge,Gerard J Criner,Xavier Soler,Michel Djandji,Amr Radwan,Paul J Rowe,Yamo Deniz,Juby A Jacob-Nara
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition of the lungs, characterized by chronic respiratory symptoms, primarily dyspnea, cough, and sputum production, due to airway and/or alveoli abnormalities that cause persistent, and often progressive, airflow obstruction. Although the underlying mechanisms responsible for COPD remain poorly understood, over the last several decades
-
Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-12 Emma D Johnson,Merete B Long,Lidia Perea,Vivian H Shih,Carlos Fernandez,Ariel Teper,David Cipolla,Eve McIntosh,Rachel Galloway,Zsofia Eke,Morven Shuttleworth,Rebecca Hull,Arietta Spinou,Anthony De Soyza,Felix C Ringshausen,Pieter Goeminne,Natalie Lorent,Charles Haworth,Michael R Loebinger,Francesco Blasi,Michal Shteinberg,Stefano Aliberti,Eva Polverino,Oriol Sibila,Amelia Shoemark,Kevin Mange,Jeffrey
RATIONALE In the WILLOW trial, the Dipeptidyl peptidase-1 inhibitor brensocatib reduced neutrophil serine protease (NSP) activity and prolonged time to first exacerbation in patients with bronchiectasis. OBJECTIVES We hypothesized that, by reducing NSPs, brensocatib would affect antimicrobial peptides, mucins, and cytokines throughout the inflammatory cascade. METHODS The WILLOW trial was a phase 2
-
Association Between Industry Payments and Prescription of Inhaled Medications. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-12 Hasan Nadeem,Lucas M Donovan,Laura C Feemster,David H Au,William B Feldman,Kevin I Duan
-
Targeting daytime normocapnia with nocturnal NIV in chronic hypercapnic COPD: the new paradigm? Thorax (IF 9.0) Pub Date : 2025-02-12 Sarah Bettina Stanzel,Wolfram Windisch
-
Invasive angiolipoma of the mediastinum and lung. Thorax (IF 9.0) Pub Date : 2025-02-12 Ziyin Shang,Yongjie Luo,Xiaoling Kang,Chun Hong,Yuan Si
-
Effect of vitamin A on adult lung function: a triangulation of evidence approach. Thorax (IF 9.0) Pub Date : 2025-02-12 Róisín Mongey,Diana A van der Plaat,Seif O Shaheen,Laura Portas,James Potts,Matthew David Hind,Cosetta Minelli
BACKGROUND Vitamin A, an essential micronutrient obtained through the diet, plays a crucial role in lung development and contributes to lung regeneration. We aimed to investigate its effect on adult lung function using triangulation of evidence from both observational and genetic data. METHODS Using data on 150 000 individuals from UK Biobank and correcting for measurement error (generalised structural
-
Pneumothorax and antibiotic use: a clue to aetiology of primary spontaneous pneumothorax? Thorax (IF 9.0) Pub Date : 2025-02-12 Rob Hallifax
-
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-10 Mario Castro, Alberto Papi, Celeste Porsbjerg, Njira L Lugogo, Christopher E Brightling, Francisco-Javier González-Barcala, Arnaud Bourdin, Mykola Ostrovskyy, Maria Staevska, Pai-Chien Chou, Liliana Duca, Ana Margarida Pereira, Charles Fogarty, Rufai Nadama, Mei Zhang, Amelie Rodrigues, Xavier Soler, Harry J Sacks, Yamo Deniz, Paul J Rowe, Juby A Jacob-Nara
BackgroundAsthma is a respiratory disease characterised by chronic airway inflammation and mucus hypersecretion. VESTIGE used functional respiratory imaging to assess changes in airway structure and function, including mucus plugging, in response to dupilumab. MethodsVESTIGE was a randomised, double-blind, placebo-controlled, phase 4 trial done at 72 research sites or academic centres in 14 countries
-
Management and mechanisms of eosinophil action in asthma: mind the gap? Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-10 Richard E K Russell
No Abstract
-
Serial Pulmonary Hemodynamics in Patients with IPF Listed for Lung Transplant. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-10 Steven D Nathan,Ho Cheol Kim,Christopher S King,Shambhu Aryal,Christopher Thomas,Zein Kattih,Oksana A Shlobin,Vikramjit Khangoora,Abhimanyu Chandel
RATIONALE Pulmonary hypertension (PH) commonly complicates idiopathic pulmonary fibrosis (IPF). However, the rate of change in pulmonary hemodynamics in IPF remains poorly defined. OBJECTIVES To examine the rate of change in pulmonary hemodynamics among patients with IPF. METHODS The rate of change in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) was examined in patients
-
Lung Cancer Screening and Incidental Findings: A Research Agenda. An Official American Thoracic Society Research Statement. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-10 Louise M Henderson,Roger Y Kim,Nichole T Tanner,Emily B Tsai,Abbie Begnaud,Farouk Dako,Michael Gieske,Kimberly Kallianos,Ilana Richman,Lori C Sakoda,Ronald G Schwartz,Joseph Yeboah,Kwun M Fong,Stephen Lam,Pyng Lee,Mary Pasquinelli,Robert A Smith,Matthew Triplette,Lynn T Tanoue,M Patricia Rivera
BACKGROUND Lung cancer screening with low-dose computed tomography (LDCT) may uncover incidental findings (IFs) unrelated to lung cancer. There may be potential benefits from identifying clinically significant IFs that warrant intervention and potential harms related to identifying IFs that are not clinically significant but may result in additional evaluation, clinician effort, patient anxiety, complications
-
Contribution of Post-TB Sequelae to Life-Years Lost from TB Disease in the United States, 2015-2019. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-10 Nicolas A Menzies,Suzanne M Marks,Yuli L Hsieh,Nicole A Swartwood,Garrett R Beeler Asay,Jacek Skarbinski,C Robert Horsburgh,Ted Cohen
RATIONALE Individuals surviving TB disease may experience chronic sequelae that reduce survival and quality-of-life. These post-TB sequalae are not generally considered in estimates of the health impact of TB disease. OBJECTIVES To estimate the TB-attributable reductions in life expectancy and quality-adjusted life expectancy for individuals developing TB disease in the United States, including post-TB
-
Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators. Thorax (IF 9.0) Pub Date : 2025-02-10 Shivanthan Shanthikumar,Liam Gubbels,Anson Tsz Chun Wong,Hannah Walker,Sarath C Ranganathan,Melanie R Neeland
BACKGROUND Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic fibrosis (CF) lung disease. Despite this, no CF-specific anti-inflammatory treatments have been developed. This is crucial even in the era of highly effective modulator therapy as recent evidence suggests that modulators alter, but may not fully resolve, pulmonary inflammation
-
Home-based pulmonary rehabilitation during outpatient-managed acute COPD exacerbation: the latest new PR model? Thorax (IF 9.0) Pub Date : 2025-02-10 Carolyn L Rochester
-
Shared Decision-Making in the ICU -Communicating with patients who speak a Language of Lesser Diffusion. Chest (IF 9.5) Pub Date : 2025-02-08 Ibrahim Serhat Karakus,Sumera R Ahmad,Amelia K Barwise
Effective bidirectional communication is crucial during end-of-life decision-making, which requires clear understanding between clinicians and patients/family members about treatment options, preferences, and goals of care. For those who have a non-English language preference (NELP), or who have difficulty speaking, reading, writing, and understanding English, interpreters are essential. However, patients
-
High Flow Nasal Cannula Liberation: Who, When, and How? Chest (IF 9.5) Pub Date : 2025-02-08 Howard Freeman,Kelly C Vranas,Sarah Tuthill,Matthew G Drake
High flow nasal cannula (HFNC) is a first-line therapy for patients with acute respiratory failure. Despite increased HFNC utilization over recent years -accelerated in part by the Coronavirus Disease 2019 pandemic - high-quality evidence to guide HFNC discontinuation is lacking. Decisions about when and how quickly to reduce flow rate, fraction of inspired oxygen, or both simultaneously are frequently
-
Physical Activity Measured by Hip-Anchored Accelerometry in Pediatric Pulmonary Hypertension: Association with Disease Severity & Estimation of Minimal Important Differences. Chest (IF 9.5) Pub Date : 2025-02-08 Mark-Jan Ploegstra,Rosaria J Ferreira,Chantal Lokhorst,Eva Gouwy,Suzanne S J Schwartz,Marlies G Haarman,Matthieu Villeneuve,Dimitri Stamatiadis,Johannes M Douwes,Rolf M F Berger
BACKGROUND Pediatric pulmonary hypertension (PH) is a severe incurable disease with poor prognosis. In pediatric PH, trial design is hampered by the absence of age-appropriate trial endpoints. This study evaluated physical activity (PA) measured by hip-anchored accelerometry as a potential trial endpoint in pediatric PH. RESEARCH QUESTIONS Is PA-accelerometry associated with disease severity, and based
-
Adult asthma hospitalisations decreased markedly in Finland and Sweden between 2006 and 2022. Thorax (IF 9.0) Pub Date : 2025-02-08 Juho E Kivistö,Jennifer L P Protudjer,Sandra Ekstrom,Jussi Karjalainen,Heini Huhtala,Lauri Lehtimäki,Inger Kull
A decreasing trend in asthma hospitalisations among Finnish and Swedish children has been reported. However, possible changes in asthma hospitalisations among adults are incompletely characterised. We aimed to investigate the incidence of adult asthma hospitalisations in Finland and Sweden from 2006 to 2022 using Finland's National Hospital Discharge Register and Sweden's National Patient Register
-
Dietary nitrate supplementation enhances exercise capacity in WHO Group 3 pulmonary hypertension: a double-blind, placebo-controlled, randomised crossover study (EDEN-OX2). Thorax (IF 9.0) Pub Date : 2025-02-08 Abdullah S Alsulayyim,Ali M Alasmari,Laura C Price,Colm McCabe,Saeed M Alghamdi,Keir Elmslie James Philip,Sara C Buttery,Matthew J Pavitt,Michael I Polkey,Matthew J Rickman,Blerina Ahmetaj-Shala,Jane A Mitchell,Rami A Alyami,Nicholas S Hopkinson
Dietary nitrate supplementation, which improves skeletal muscle oxygen utilisation, vascular endothelial function and exercise capacity in people with chronic obstructive pulmonary disease, may benefit other lung conditions. In a double-blind, placebo-controlled, crossover study, in 19 adults with Group 3 pulmonary hypertension who desaturated during exercise, 140 mL of nitrate-rich beetroot juice
-
Accumulating evidence supports advanced bronchoscopy as a modality of choice for difficult-to-reach peripheral lung nodules, but questions remain. Thorax (IF 9.0) Pub Date : 2025-02-08 Rafael Paez,Fabien Maldonado
-
Incidental finding of leukaemic pulmonary infiltration confirmed by flow cytometry of BAL fluid. Thorax (IF 9.0) Pub Date : 2025-02-08 Matthew Wells,Aaron Morjaria,William Cooper,Sophie Otton,Huzaifa I Adamali
-
Is NEWS2 the optimal evidence-based surveillance tool for all respiratory patients or does it just represent the beginning of an iterative development process? Thorax (IF 9.0) Pub Date : 2025-02-08 Dominick Shaw,Andrew W Fogarty
Medical practice is built on the foundations of evidence-based medicine. Hence, the more common the clinical intervention, the more comprehensive the evidence on which that intervention should be based. Although the widespread adoption of a national early warning score in the UK has led to improvements in the delivery of care, it should be considered as providing a foundation that can be refined and
-
Continuous Monitoring for Atrial Fibrillation in Individuals at Increased Risk of Acute Exacerbations of COPD. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-07 David M MacDonald,Trent Fischer,Selcuk Adabag,Shakeel Amanullah,Jose Diaz,Philip Diaz,Ken M Kunisaki,Pamela L Lutsey,Christine H Wendt
-
Mucoid Staphylococcus aureus - Prevalence and Association with Lung Function in People with Cystic Fibrosis. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-07 Christine H Rumpf,Timo Janssen,Robert Jonathan Hait,Karin Romme,Clemens Decker,Janne Peters,Corinna Czowalla,Susanne Deiwick,Dennis Görlich,Angelika Dübbers,Jörg Große-Onnebrink,Christina Kessler,Peter Küster,Holger Schültingkemper,Helge Hebestreit,Ute Graepler-Mainka,Silke van Koningsbruggen-Rietschel,Tom Schildberg,Sabine Renner,Susanne Nährig,Bettina Wollschläger,Anne Schlegtendal,Sivagurunathan
RATIONALE The mucoid phenotype of Staphylococcus aureus is caused by adaptation. Excessive biofilm formation associated with a protective effect for mucoid S. aureus was observed in isolates from respiratory samples of people with cystic fibrosis (pwCF). However, there is little knowledge about the prevalence of mucoid S. aureus in pwCF and a potential association with CF lung disease. METHODS A prospective
-
Real-World Smoking History Documentation and Identification of Lung Cancer Screening Candidates. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-07 Kyle M Koster,Abigail Feinberg,Keith Sigel,Juan Wisnivesky,Cardinale Smith,Minal Kale
-
Long-Term Fine Particulate Matter Exposure on Lung Cancer Incidence and Mortality in Chinese Nonsmokers. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-07 Meng Zhu,Yuting Han,Yuanlin Mou,Xia Meng,Chen Ji,Xia Zhu,Canqing Yu,Dianjianyi Sun,Ling Yang,Qiufen Sun,Yiping Chen,Huaidong Du,Juncheng Dai,Zhengming Chen,Zhibin Hu,Jun Lv,Guangfu Jin,Hongxia Ma,Haidong Kan,Liming Li,Hongbing Shen
Rationale: The association between fine particulate matter (PM2.5) and lung cancer incidence in non-smokers (LCINS) remains inconsistent. Objectives: To investigate the association between long-term PM2.5 exposure and LCINS in a Chinese population and to assess the modifying effect of genetic factors. Methods: Time-dependent Cox proportional hazard models were employed to evaluate the hazard ratios
-
How bad is your cough? The McMaster Cough Severity Questionnaire as a new tool to measure chronic cough. Eur. Respir. J. (IF 16.6) Pub Date : 2025-02-06 Richard D Turner,Surinder S Birring
-
Recurrent respiratory papillomatosis in adults with lower respiratory tract involvement: a retrospective study of the OrphaLung and GETIF networks. Eur. Respir. J. (IF 16.6) Pub Date : 2025-02-06 Romy Ratsihorimanana,Thomas Maitre,Matthieu Dusselier,Minh Triet Ngo,Gilles Mangiapan,Clément Fournier,Arnaud Bourdin,Stephane Jouneau,Maroun Matar,Nicolas Favrolt,Thomas Egenod,Jean Michel Vergnon,Delphine Wermert,Jean François Boitiaux,Raphael Borie,Raffaele Caliandro,Olivia Freynet,Valérie Gounant,Julie Mankikian,Juliette Camuset,Alexandre Elabbadi,Antoine Parrot,Julien Calvani,Marc Fortin,Nicolas
BACKGROUND Recurrent respiratory papillomatosis (RRP) is a rare respiratory disease primarily caused by chronic human papillomavirus (HPV) infection of serotypes 6 and 11. It manifests in childhood (juvenile-onset recurrent respiratory papillomatosis [JoRRP]) and adulthood (adult-onset recurrent respiratory papillomatosis [AoRRP]), leading to progressive obstruction by papillomas in the upper airway
-
Prenatal exposure to greenness and early childhood pneumonia: A nationwide study in Japan. Eur. Respir. J. (IF 16.6) Pub Date : 2025-02-06 Akihiro Shiroshita,Yuki Kataoka,Qianzhi Wang,Naoki Kajita,Keisuke Anan,Yusaku Shibata,Nobuyuki Yajima
-
First Assessment of Photon-Counting CT for Virtual Bronchoscopic Navigation. Eur. Respir. J. (IF 16.6) Pub Date : 2025-02-06 Marcel Opitz,Faustina Funke,Kaid Darwiche,Sebastian Zensen,Marko Frings,Luca Salhöfer,Johannes Haubold,Michael Forsting,Fabian Doerr,Servet Bölükbas,Filiz Oezkan,Jane Winantea,Hanna Zellerhoff,Rüdiger Karpf-Wissel,Johannes Wienker,Dirk Westhölter,Matthias Welsner,Christian Taube,Erik Büscher
-
Cardiovascular risk assessment in patients with COPD: reduce, reuse and recycle. Eur. Respir. J. (IF 16.6) Pub Date : 2025-02-06 Miguel Divo,Ciro Casanova,Victor Pinto-Plata
-
Reply: A recommendation for increased airflow to relieve breathlessness: evidence in context is a strength of the GRADE approach. Eur. Respir. J. (IF 16.6) Pub Date : 2025-02-06 Anne E Holland,Claudia Bausewein,Natasha Smallwood,Magnus Ekström
-
ERS guideline recommendation on airflow for breathlessness: the pitfalls of applying GRADE evidence ratings to complex non-pharmacological interventions. Eur. Respir. J. (IF 16.6) Pub Date : 2025-02-06 Tim Luckett,Flavia Swan,Joseph Clark,Mary Roberts,Mark Pearson,Ann Hutchinson,David Currow,Slavica Kochovska,Michael Crooks,Tracy Smith,Miriam Johnson
-
Drug-induced lung disease: unwanted collateral damage. Eur. Respir. J. (IF 16.6) Pub Date : 2025-02-06 Yet H Khor,Martin Kolb
-
A step closer to the holy grail? The utility of extracorporeal photopheresis in lung transplantation. Eur. Respir. J. (IF 16.6) Pub Date : 2025-02-06 Jens Gottlieb,Reece Jefferies
-
Tracing the origins of fibrotic fibroblasts: does the name matter? Look at the genes! Eur. Respir. J. (IF 16.6) Pub Date : 2025-02-06 Arnaud A Mailleux,Aurélien Justet
-
Modified Cuff Leak Test for Predicting the Risk of Reintubation in Patients with Invasive Mechanical Ventilation: A Multicenter, Single-Blind, Randomized Controlled Trial. Chest (IF 9.5) Pub Date : 2025-02-06 Xiao Tang,Yan-Mei Gu,Yuan Shi,Zhi-Ming Li,Rui Cao,Sheng-Gui Lu,Yan-Bin Wu,Yun-Feng Tao,Zi-Yan Sun,Yong-Jie Yin,Cheng-Yi Liu,Xiao-Bin Tang,Gui-Fen Gan,Xue-Jun Qin,Dong Yin,Hong-Bin Zhao,Cheng-Ying Liu,Lei Zhang,Ping Fang,Ling-Shuang Du,Li Li,Hai Tan,Meng Li,Ying-Ting Zuo,Bing Sun,
BACKGROUND The cuff leak test (CLT) is an important tool to assess the risk of upper airway obstruction after extubation. RESEARCH QUESTION Does modified CLT approach have superior ability in predicting re-intubation compared with traditional method? STUDY DESIGN AND METHODS This was a prospective, multicenter, randomized control trial. The primary end point was the incidence of the need for reintubation
-
Acute pulmonary embolism in children and adolescents in the USA (2016 and 2019): a nationwide retrospective cohort study Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-04 Simon Wolf, Luca Valerio, Nils Kucher, Stavros V Konstantinides, Irene L M Klaassen, C Heleen van Ommen, Cihan Ay, Frederikus A Klok, Suzanne C Cannegieter, Stefano Barco
BackgroundEpidemiological data on acute pulmonary embolism among children and adolescents are sparse and only date back to the 2000s. We aimed to establish annual estimates and age-stratified and sex-stratified indicators of acute pulmonary embolism among children and adolescents aged 0–19 years. MethodsWe did a retrospective, nationwide, patient-level analysis of the Kids’ Inpatient Database, including
-
PH and CKD: unravelling the cardiorenal nexus Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-04 Faeq Husain-Syed, Uta Erdbrügger, Susmita Sahoo, Thorsten Wiech, Claudio Ronco, Khodr Tello
No Abstract
-
Expanding CFTR modulator access to benefit all patients who are waiting for a lung transplant Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-04 Rossa Brugha, Kavita Dave, Vicky Gerovasili, Amit Adlakha
No Abstract
-
Thank you to The Lancet Respiratory Medicine's clinical and statistical peer reviewers in 2024 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-04
No Abstract
-
Treatment strategy for EGFR mutated NSCLC Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-03 Yusuke Okuma
No Abstract
-
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-03 Yuankai Shi, Yanzhen Guo, Xingya Li, Lin Wu, Zhaohong Chen, Sheng Yang, Minghong Bi, Yanqiu Zhao, Wenxiu Yao, Huiqing Yu, Ke Wang, Wenhua Zhao, Meili Sun, Liangming Zhang, Zhiyong He, Yingcheng Lin, Jianhua Shi, Bo Zhu, Lijun Wang, Yueyin Pan, Anqi Zhou
BackgroundThis study aimed to compare the efficacy and safety of rezivertinib (BPI-7711) and gefitinib as first-line therapies in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC). MethodsThis multicentre, double-blind, randomised, phase 3 study (REZOR) included eligible patients from 50 hospitals across China. Those who had been histologically or cytologically
-
Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-03 Ganfeng Luo, Yanting Zhang, Harriet Rumgay, Eileen Morgan, Oliver Langselius, Jerome Vignat, Murielle Colombet, Freddie Bray
BackgroundLung cancer is the most common cancer worldwide, yet the current epidemiological profile of lung-cancer incidence by histological subtype is only partly understood. We aimed to assess geographical variation in incidence of lung cancer by subtype worldwide in 2022, geographical variation in adenocarcinoma incidence attributable to ambient particulate matter (PM) pollution worldwide in 2022
-
Charting a Path Toward Diagnostic Excellence and Equity in Thoracic Oncology: The Critical Role of Interventional and Onco-Pulmonologists. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-03 Roger Y Kim,Christopher M Kapp,Jeffrey Thiboutot,M Patricia Rivera,A Christine Argento
-
Trajectories of interferon-gamma release assay results over two years in independent cohorts from China, South Africa, Tanzania, and the United States. Chest (IF 9.5) Pub Date : 2025-02-03 Cheng Chen,Hao Xue,C Robert Horsburgh,Maryam Amour,Mark Hatherill,Michele Tameris,C Fordham von Reyn,Christiaan Rees,Ye Shen,Helen McShane,Alberto L García-Basteiro,Donglin Liu,Yijun Wang,Ruvandhi R Nathavitharana,Edward A Graviss,Yan Shao,Qiao Liu,Wei Lu,Limei Zhu,Leonardo Martinez
BACKGROUND There is an ongoing debate about whether clearance of Mycobacterium tuberculosis infection occurs and at what magnitude. Recent studies quantifying 'uncertainty zones' of interferon-gamma release assays (IGRA) provide a more stringent estimate of reversion, potentially indicating clearance. RESEARCH QUESTION When accounting for 'uncertainty zones' through stringent cutoffs, what are the
-
Extracellular vesicles offer enticing opportunities to target and treat lung inflammation. Thorax (IF 9.0) Pub Date : 2025-02-03 Sally Yunsun Kim
-
Availability, cost and affordability of essential medicines for smoking cessation in low-income and middle-income countries: a cross-sectional study. Thorax (IF 9.0) Pub Date : 2025-02-03 Catherine Plum,Marie Stolbrink,Obianuju Ozoh,Shamanthi Jayasooriya,Rebecca Nightingale,Kevin Mortimer,David Halpin
Smoking cessation is more effective when supported by medicines. Data on the availability, cost and affordability of these treatments in low-income and middle-income countries (LMIC) are limited. Cross-sectional data for smoking cessation medications were collected from pharmacies, healthcare facilities and central medicine stores in 60 LMIC (2022-2023). Medications had varying availability, large
-
Pulmonary rehabilitation: one size does not fit all. Thorax (IF 9.0) Pub Date : 2025-02-03 Narelle S Cox,Anne E Holland
-
Chronic obstructive pulmonary disease: new therapies and old needs Lancet Respir. Med. (IF 38.7) Pub Date : 2025-01-31 Nicholas S Hopkinson
No Abstract
-
Marcel Proust (1871–1922): a historico-medical review of his fatal asthma Lancet Respir. Med. (IF 38.7) Pub Date : 2025-01-31 Donatella Lippi, Elena Varotto, Francesco M Galassi, Francesco Baldanzi
Section snippets The historico-medical contextMarcel Proust's medical conditions have been widely studied, with detailed reconstruction of the history of his illness and the influence it had on his artistic production. Proust had recurrent attacks of severe asthma from the age of 9 years, later developing an obstructive lung disease, before dying of infectious pneumonia at the age of 51 years.Marcel
-
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials Lancet Respir. Med. (IF 38.7) Pub Date : 2025-01-31 Surya P Bhatt, Klaus F Rabe, Nicola A Hanania, Claus F Vogelmeier, Mona Bafadhel, Stephanie A Christenson, Alberto Papi, Dave Singh, Elizabeth Laws, Paula Dakin, Jennifer Maloney, Xin Lu, Deborah Bauer, Ashish Bansal, Raolat M Abdulai, Lacey B Robinson
BackgroundDupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13, which are key drivers of type 2 inflammation. We aimed to characterise the efficacy and safety of dupilumab in patients with COPD and type 2 inflammation. MethodsFor this pooled analysis, we pooled and analysed data from all patients in the intention-to-treat populations of the phase 3,
-
Sleep Problems in Sickle Cell Disease. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2025-02-01 Krista Reiling,Sonal Malhotra
-
An Immunocompetent 56-Year-Old Woman With Multiple Enlarged Lymph Nodes and Recurrent Fevers. Chest (IF 9.5) Pub Date : 2025-02-01 Xiao Shi,Changxiu Ma,Jun Fei,Hailong Chen,Zhou Liu,Naifang Ye,Li Ma,Hong Zhao,Dahai Zhao
A 56-year-old woman was admitted to our hospital, presenting with a history of recurrent fevers persisting for over 2 months. The febrile episode was self-limiting, accompanied by cough without significant expectoration, with the fever predominantly manifesting during the afternoon and evening hours. Furthermore, there were no concurrent symptoms indicative of chest tightness, wheezing, dyspnea, or
-
Enhancing the Study of Air Pollution, Metabolomic Signatures, and Chronic Respiratory Disease Risk: Addressing Dietary, Noise, and Exposure Factors. Chest (IF 9.5) Pub Date : 2025-02-01 Zhangbing Zhou,Liu Wang,Yunfeng Chen
-
A 21-Year-Old Man With Unilateral Chest Pain, Lobar Consolidation, and Pleural Effusion. Chest (IF 9.5) Pub Date : 2025-02-01 Mckenna Wade,Kathryn Hughes,Russell Miller,Stephen Hughes
A 21-year-old man with a history of glucose-6-phosphate dehydrogenase deficiency experienced an acute onset of atraumatic left upper abdominal and flank pain. An initial contrast-enhanced CT scan of the chest, abdomen, and pelvis revealed a consolidation in the left lower lobe, a small pleural effusion, and enlarged mesenteric lymph nodes. The patient was prescribed nonsteroidal antiinflammatory drugs
-
Enhancing the Understanding of Pregnancy Outcomes in Critical Illness: Addressing Unexplored Variables and Time-Related Bias. Chest (IF 9.5) Pub Date : 2025-02-01 Shumin He,GuangYao Wang,Qiong Yi